{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T22:47:31Z","timestamp":1776725251220,"version":"3.51.2"},"reference-count":23,"publisher":"Georg Thieme Verlag KG","issue":"04","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Klin Monbl Augenheilkd"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Introduction Following the expiration of ranibizumab\u02bcs (Lucentis) patent, the biosimilar ranibizumab-nuna (Byooviz) offers an alternative intravitreal medication with identical indications. However, real-world data on its efficacy remain limited. This study aimed to investigate the efficacy and safety of retinal disorders in patients who were switched from Lucentis to Byooviz.<\/jats:p>\n                  <jats:p>Methods This retrospective, single-center study assessed adult patients previously treated with intravitreal Lucentis and switched to Byooviz. We evaluated structural and functional outcomes based on Snellen visual acuity (VA), fundoscopy, and optical coherence tomography (OCT) parameters, and treatment safety. Disease activity was classified as active or inactive, with neovascular activity defined as retinal pigment epithelial detachments, intra- or subretinal fluid, subretinal hyperreflective material, or macular hemorrhage on OCT or fundoscopy.<\/jats:p>\n                  <jats:p>Results Between June 2021 and December 2024, we identified 31 patients, 21 (67.7%) of whom were female. Median (IQR, range) age was 82 (76.5 to 85.5, 49 to 91) years. The most common indication was neovascular age-related macular degeneration (61.3%), followed by macular edema (ME) due to retinal vein occlusion (22.6%), diabetic ME (9.7%), and secondary choroidal neovascularization (6.5%). Right and left eyes were nearly equally represented (48.4% vs. 51.6%). The median (IQR) injection numbers were 15 (10 to 40) for Lucentis and 8 (5 to 10.5) for Byooviz. After the switch, VA improved in 8 eyes (25.8%), was unchanged in 10 (32.3%), and worsened in 13 (41.9%). Disease activity decreased in 6 eyes (20%), increased in 3 (10%), and remained stable in 22 (70%). Treatment intervals shortened in 8 (25.8%) patients and extended in 14 (45.2%). No cases of endophthalmitis or other complications occurred.<\/jats:p>\n                  <jats:p>Discussion Switching from Lucentis to Byooviz was generally well tolerated, with anatomical disease stability maintained in most patients. Certain decline in VA is also be observed in real-world outcomes for Lucentis and may reflect underlying disease progression rather than reduced efficacy of the biosimilar. Overall, Byooviz seems to be a viable alternative for patients previously treated with Lucentis.<\/jats:p>","DOI":"10.1055\/a-2803-9757","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T22:34:26Z","timestamp":1776724466000},"page":"434-439","source":"Crossref","is-referenced-by-count":0,"title":["Switching to the Biosimilar Ranibizumab-nuna for the Intravitreal Treatment of Retinal Diseases \u2013 a Real-World Study"],"prefix":"10.1055","volume":"243","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2037-4766","authenticated-orcid":false,"given":"Sadiq","family":"Said","sequence":"additional","affiliation":[{"name":"Augenklinik Wettingen, Wettingen, Switzerland"},{"name":"Department of Ophthalmology, University Hospital Zurich, University of Zurich, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Knecht-B\u00f6sch","sequence":"additional","affiliation":[{"name":"Augenklinik Wettingen, Wettingen, Switzerland"},{"name":"Department of Ophthalmology, University of Zurich, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascal","family":"Knecht-Bosch","sequence":"additional","affiliation":[{"name":"Augenklinik Wettingen, Wettingen, Switzerland"},{"name":"Department of Ophthalmology, University of Zurich, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2026,4,20]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1177\/2474126420971982","article-title":"A History of Anti-VEGF Inhibitors in the Ophthalmic Literature: A Bibliographic Review","volume":"5","author":"T D Whitescarver","year":"2021","journal-title":"J Vitreoretin Dis"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"P J Rosenfeld","year":"2006","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1177\/24741264211028441","article-title":"Intravitreal Injection Therapy: Current Techniques and Supplemental Services","volume":"5","author":"L A Lam","year":"2021","journal-title":"J Vitreoretin Dis"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1007\/s00417-017-3647-4","article-title":"Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti-vascular endothelial growth factor therapy of macular diseases","volume":"255","author":"P Lanzetta","year":"2017","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2147\/PHMT.S391591","article-title":"Role of Anti-Vascular Endothelial Growth Factor (Anti-VEGF) in the Treatment of Retinopathy of Prematurity: A Narrative Review in the Context of Middle-Income Countries","volume":"14","author":"M R Dogra","year":"2023","journal-title":"Pediatric Health Med Ther"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.2147\/DDDT.S427416","article-title":"Faricimab: Transforming the Future of Macular Diseases Treatment \u2013 A Comprehensive Review of Clinical Studies","volume":"17","author":"G D Panos","year":"2023","journal-title":"Drug Des Devel Ther"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1080\/09286586.2024.2310854","article-title":"Trends in Anti-Vascular Endothelial Growth Factor Original Medicare Part B Claims in the United States, 2014\u20132019","volume":"31","author":"S Desai","year":"2024","journal-title":"Ophthalmic Epidemiol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.2147\/OPTH.S180393","article-title":"Biosimilars in ophthalmology: \u201cIs there a big change on the horizon?\u201d","volume":"12","author":"A Sharma","year":"2018","journal-title":"Clin Ophthalmol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1001\/jamaophthalmol.2022.5403","article-title":"Immunogenicity With Ranibizumab Biosimilar SB11 (Byooviz) and Reference Product Lucentis and Association With Efficacy, Safety, and Pharmacokinetics: A Post Hoc Analysis of a Phase 3 Randomized Clinical Trial","volume":"141","author":"N M Bressler","year":"2023","journal-title":"JAMA Ophthalmol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.2174\/0115748863360017250509063745","article-title":"Biosimilar Regulations: Current Framework and Future Prospects","author":"S Kaur","year":"2025","journal-title":"Curr Drug Saf"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1136\/bjophthalmol-2021-319637","article-title":"Biosimilar SB11 versus reference ranibizumab in neovascular age-related macular degeneration: 1-year phase III randomised clinical trial outcomes","volume":"107","author":"N M Bressler","year":"2023","journal-title":"Br J Ophthalmol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1186\/s12874-022-01768-6","article-title":"Real-world data: a brief review of the methods, applications, challenges and opportunities","volume":"22","author":"F Liu","year":"2022","journal-title":"BMC Med Res Methodol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1001\/jamaophthalmol.2024.3458","article-title":"Aflibercept Biosimilar MYL-1701P vs. Reference Aflibercept in Diabetic Macular Edema: The INSIGHT Randomized Clinical Trial","volume":"142","author":"S B Bressler","year":"2024","journal-title":"JAMA Ophthalmol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1001\/jamaophthalmol.2023.2260","article-title":"Efficacy and Safety of the Aflibercept Biosimilar SB15 in Neovascular Age-Related Macular Degeneration: A Phase 3 Randomized Clinical Trial","volume":"141","author":"S J Woo","year":"2023","journal-title":"JAMA Ophthalmol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1097\/IAE.0000000000004174","article-title":"Efficacy and Safety of the Proposed Biosimilar Aflibercept, SDZ-AFL, in Patients with Neovascular Age-Related Macular Degeneration: 52-Week Results from the Phase 3 Mylight Study","volume":"44","author":"A F Bordon","year":"2024","journal-title":"Retina"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1007\/s00417-020-04730-8","article-title":"Beneficial switch from aflibercept to ranibizumab for the treatment of refractory neovascular age-related macular degeneration","volume":"258","author":"L M Marquis","year":"2020","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1097\/IAE.0000000000003626","article-title":"Anti-Vascular Endothelial Growth Factor Biosimilars in Ophthalmology","volume":"42","author":"P K Kaiser","year":"2022","journal-title":"Retina"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1080\/14712598.2023.2176218","article-title":"Biosimilars for retinal diseases: United States-Europe awareness survey (Bio-USER \u2013 survey)","volume":"23","author":"A Sharma","year":"2023","journal-title":"Expert Opin Biol Ther"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/s41433-019-0636-3","article-title":"Ophthalmic biosimilars and biologics-role of endotoxins","volume":"34","author":"A Sharma","year":"2020","journal-title":"Eye (Lond)"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1177\/24741264251322213","article-title":"Biosimilar Ranibizumab (Ranieyes) Safety and Efficacy in the Real World: BRESER Study","author":"A Sharma","year":"2025","journal-title":"J Vitreoretin Dis"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1097\/IAE.0000000000003556","article-title":"A Consensus on Risk Mitigation for Brolucizumab in Neovascular Age-Related Macular Degeneration: Patient Selection, Evaluation, and Treatment","volume":"42","author":"F G Holz","year":"2022","journal-title":"Retina"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.ophtha.2020.11.011","article-title":"Risk of Inflammation, Retinal Vasculitis, and Retinal Occlusion-Related Events with Brolucizumab: Post Hoc Review of HAWK and HARRIER","volume":"128","author":"J Mones","year":"2021","journal-title":"Ophthalmology"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.ophtha.2007.05.028","article-title":"Comparison of visual acuity in macular degeneration patients measured with Snellen and early treatment diabetic retinopathy study charts","volume":"115","author":"I A Falkenstein","year":"2008","journal-title":"Ophthalmology"}],"container-title":["Klinische Monatsbl\u00e4tter f\u00fcr Augenheilkunde"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2803-9757.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T22:35:18Z","timestamp":1776724518000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2803-9757"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":23,"journal-issue":{"issue":"04","published-online":{"date-parts":[[2026,4,20]]},"published-print":{"date-parts":[[2026,4]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2803-9757","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0023-2165","1439-3999"],"issn-type":[{"value":"0023-2165","type":"print"},{"value":"1439-3999","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]}}}